What question did this study set out to answer?

To evaluate the dose response of paricalcitol on PTH and FGF23 levels in end-stage renal failure patients.

December 11, 2025

Dose response of PTH and FGF23 to paricalcitol in patients with end-stage renal failure on chronic intermittent hemodialysis

Key Points

To evaluate the dose response of paricalcitol on PTH and FGF23 levels in end-stage renal failure patients.
Administered paricalcitol to patients on chronic intermittent hemodialysis
Measured PTH and FGF23 levels at 6 and 12 weeks
Compared results with a placebo group
Paricalcitol significantly reduced PTH levels compared to placebo
No elevation in FGF23 levels was noted during the short study duration
Lower starting doses of paricalcitol may help manage PTH effectively while preventing spikes in FGF23

Abstract

Treatment with paricalcitol resulted in a significant reduction in PTH levels at both 6 and 12 weeks compared to placebo. The suppression of PTH levels with paricalcitol was possible without elevating FGF23 within the restrictions of this short duration study, at least if over-suppression of PTH is avoided by dose adaption. Our findings suggest a cautious lower oral paricalcitol starting dose to mitigate the initial spike in FGF23 while effectively managing PTH levels.

KI fragen

Bookmark

View Full Paper